Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 28, 2009 Brian Orelli	Now That's Healthy Innovation UnitedHealth lowers costs through an adherence-incentive program.
Managed Care November 2001	Drug Discount Cards May Not Be Full Answer A fair number of consumers have turned to discount prescription cards to help pay for medications but the value of these cards is in doubt...
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool June 2, 2010 Brian Orelli	Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it."
Managed Care December 2004 John Carroll	Pfizer Touts Medicaid Data In Arguing That DM Works The pharmaceutical giant Pfizer says that its disease management program saved Florida $42 million, but a state watchdog group remains unconvinced.
Chemistry World May 7, 2013 Phillip Broadwith	Buy Viagra online - direct from the manufacturer Pharmaceutical giant Pfizer is cutting out the pharmacist middle-man by setting up a website for Viagra (sildenafil citrate) sales.
The Motley Fool September 2, 2008 Brian Orelli	Lipitor Is Back on the Tube Direct-to-consumer ads have to walk a line.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
Managed Care December 2002	Drug-discount program's effectiveness hindered by lack of use California offers a prescription drug discount program that allows Medicare beneficiaries to get discounts just by showing their Medicare cards to pharmacists. Unfortunately, a majority of those eligible -- both those with and without drug coverage -- have never heard of the program.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
The Motley Fool January 13, 2009 Dayana Yochim	Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool November 8, 2006 Michael P. Cecil	CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool March 23, 2009 Brian Orelli	Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool September 7, 2007 Brian Orelli	Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications.
The Motley Fool May 10, 2011 Brian Orelli	Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet.
The Motley Fool January 12, 2010 Dayana Yochim	6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab.
Managed Care April 2002	How Much Of a Discount Do Cards Offer? Pharmaceutical and chain drug store industry insiders say that the Bush administration's push to provide prescription drugs to the low-income elderly lacks important ingredients: details and money...
The Motley Fool February 14, 2008 Brian Orelli	A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product.
The Motley Fool November 21, 2008 Brian Orelli	Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
BusinessWeek June 12, 2006 Michael Arndt	Big Pharma's Nurse Will See You Now Drug companies are hiring RNs to educate patients - and boost marketing.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
BusinessWeek December 11, 2006 Michael Arndt	Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West.
The Motley Fool September 28, 2007 Brian Orelli	Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool December 1, 2009 Brian Orelli	Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
Pharmaceutical Executive January 1, 2006 Bill Shearer	Patient Assistant Programs and Medicare Part D About 2.5 million low-income seniors who participate in prescription access programs are eligible for drug coverage under Medicare Part D - but the programs are out of alignment.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
Managed Care September 2004	Cost-Related Underuse of Heart Meds Leads to Cardiac Complications The study is significant because it is the first nationally representative longitudinal study to demonstrate that patients with serious chronic illnesses experience adverse health events when they restrict their use of prescription drugs due to cost.
Managed Care June 2002 Jeffry R. Ellis	Third-Party Payers Don't Realize Burdens Placed on Pharmacists PBMs and HMOs, by imposing a workload that doesn't allow enough time for needed functions, seem to want pharmacists to fail, this author asserts.
The Motley Fool July 7, 2004 Charly Travers	Pfizer Wants to Be Your Pfriend It seems that the pharmaceutical is limiting its profits in certain markets on its own terms in the hopes that concessions will be sufficient to keep from being handcuffed by Congress.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool October 9, 2008 Brian Orelli	When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management.
Managed Care December 2005	Polypharmacy Interventions Result in Sustained Decreases A drug safety study found a decline in drug costs and in numbers of prescriptions in a population at high risk for adverse drug events brought on by polypharmacy.
The Motley Fool April 29, 2011 Brian Orelli	Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib.
Managed Care December 2000	How To Save Money on Prescriptions There are ways for low-income groups to avoid paying top dollar for prescriptions. Here's one way physicians can educate consumers...
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.